Anti-E in pregnancy

Authors

  • P. Moran,

    Research Registrar
    1. Departments of Obstetrics and Gynaecology and Haematology, Royal Victoria Infirmary, Newcastle upon Tyne
    Search for more papers by this author
  • S. C. Robson,

    Professor (Fetal Medicine)
    1. Departments of Obstetrics and Gynaecology and Haematology, Royal Victoria Infirmary, Newcastle upon Tyne
    Search for more papers by this author
  • M. M. Reid

    Consultant (Haematology), Corresponding author
    1. Departments of Obstetrics and Gynaecology and Haematology, Royal Victoria Infirmary, Newcastle upon Tyne
      Correspondence: Dr M. M. Reid, Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
    Search for more papers by this author

Correspondence: Dr M. M. Reid, Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.

Abstract

Since the introduction of anti-Rhesus (Rh) D prophylaxis for RhD-negative women, other Rh and non-Rh red cell alloantibodies have become relatively more important and are now responsible for the greater proportion of haemolytic disease of the newborn. Anti-C and anti-E are the most commonly implicated non-D Rh antibodies in the pathogenesis of haemolytic disease of the newborn1. In 1977 Pepperell et al.2 reported the outcome of 44 women with anti-E. This is the only published series that investigates the implications of anti-E during pregnancy. The present report presents a retrospective study of the outcome of 122 pregnancies in which anti-E was the sole alloantibody detected.

Ancillary